N@N

PPD Names Henrietta Ukwu, M.D., Senior Vice President of Global Regulatory Affairs

^{Published on 2010-07-14 13:20:42 - Market Wire}
 

WILMINGTON, N.C.--([ BUSINESS WIRE ])--PPD, Inc. (Nasdaq: PPDI) announced it has appointed Henrietta Ukwu, M.D., FACP, FRAPS, as senior vice president of global regulatory affairs. She will have global responsibility for regulatory services across all PPD lines of business and provide clinical vaccine expertise to advance the companya™s vaccines and biologics operations.

"She has a well-earned reputation for building strategic regulatory teams and leading initiatives to drive regulatory excellence, which will help PPD continue to deliver superior regulatory assessment and strategies for all stages of our clientsa™ product development."

aDr. Ukwu brings exceptional leadership, product development and global regulatory expertise to PPD, having held senior positions in the pharmaceutical industry for the past 18 years,a said Christine Dingivan, M.D., chief medical officer of PPD. aShe has a well-earned reputation for building strategic regulatory teams and leading initiatives to drive regulatory excellence, which will help PPD continue to deliver superior regulatory assessment and strategies for all stages of our clientsa™ product development.a

Dr. Ukwu most recently served as vice president of global regulatory affairs at Wyeth Pharmaceuticals, Inc., now Pfizer, Inc., where her leadership and responsibility spanned vaccines, biologics and pharmaceuticals and all major regions including the United States, Canada, Asia Pacific, Latin America, Europe, Middle East and Africa. During this six-year period, Dr. Ukwua™s responsibilities included overseeing strategic global product development and registration plans, human subject protection for clinical and preclinical development, and ensuring rigorous global regulatory standards and successful registration of new drugs and biologics.

Prior to joining Wyeth Pharmaceuticals, Dr. Ukwu spent nearly 12 years with Merck & Co., Inc., where she was promoted to positions of increasing responsibility, including head of vaccine regulatory development, vice president of global regulatory affairs and global regulatory policy.

Since joining the pharmaceutical industry, Dr. Ukwu has overseen the successful original regulatory development, filings and approvals of 14 new products.

Dr. Ukwu earned her medical and surgical degrees from the University of Jos School of Medicine in Nigeria. She completed her residency in internal medicine at Baptist Hospital in Nashville, Tenn., and her fellowship in infectious diseases at Vanderbilt University in Nashville. She is a fellow of the American College of Physicians (FACP) and the Regulatory Affairs Professional Society (FRAPS) and is a professor at the Graduate School of Pharmacy at Temple University in Ambler, Pa.

PPD is a leading global contract research organization, celebrating 25 years of providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 41 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit [ www.ppdi.com ].

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the above named employeea™s performance and contributions to PPD and its regulatory affairs business, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; competition within the outsourcing industry; rapid technological advances that make our products and services less competitive; success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; risks associated with and dependence on collaborative relationships; risks associated with acquisitions and investments, such as impairments; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.